LYEL - Lyell Immunopharma - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

LYEL is currently covered by 2 analysts with an average price target of $10.73. This is a potential upside of $1.03 (10.62%) from yesterday's end of day stock price of $9.7.

Lyell Immunopharma's activity chart (see below) currently has 6 price targets and 15 ratings on display. The stock rating distribution of LYEL is 36.36% BUY, 54.55% HOLD and 9.09% SELL.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 41.67% with an average time for these price targets to be met of 136 days.

Highest price target for LYEL is $1, Lowest price target is $1, average price target is $1.

Most recent stock forecast was given by MITCHELL KAPOOR from HC WAINWRIGHT on 16-Apr-2025. First documented stock forecast 12-Jul-2021.

Best performing analysts who are covering LYEL - Lyell Immunopharma:

Mitchell Kapoor Geoff Meacham Matthew Harrison Salveen Richter

Currently out of the existing stock ratings of LYEL, 4 are a BUY (36.36%), 6 are a HOLD (54.55%), 1 are a SELL (9.09%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

$1

$-8.74 (-89.73%)

$1

2 months 1 days ago
(16-Apr-2025)

12/12 (100%)

$0.56 (127.27%)

373

Sell

$1

$-8.74 (-89.73%)

$6

7 months 18 days ago
(30-Oct-2024)

2/3 (66.67%)

$0.14 (16.28%)

171

Hold

$4

$2.9 (263.64%)

$7

2 years 4 months 24 days ago
(24-Jan-2023)

0/3 (0%)

$0.96 (31.58%)

Buy

$7

$5.9 (536.36%)

$30

2 years 7 months 6 days ago
(11-Nov-2022)

0/2 (0%)

$2.47 (54.53%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is LYEL (Lyell Immunopharma) average time for price targets to be met?

On average it took 136 days on average for the stock forecasts to be realized with a an average price target met ratio 41.67

Which analyst has the current highest performing score on LYEL (Lyell Immunopharma) with a proven track record?

MITCHELL KAPOOR

Which analyst has the current lower performing score on LYEL (Lyell Immunopharma) with a proven track record?

SALVEEN RICHTER

Which analyst has the most public recommendations on LYEL (Lyell Immunopharma)?

Mitchell Kapoor has 10 price targets and 7 ratings on LYEL

Which analyst is the currently most bullish on LYEL (Lyell Immunopharma)?

Salveen Richter with highest potential upside - $5.9

Which analyst is the currently most reserved on LYEL (Lyell Immunopharma)?

Mitchell Kapoor with lowest potential downside - -$8.74

Lyell Immunopharma in the News

Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025

SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) — Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced that an abstract highlighting new clinical data from the Phase 1/2 trial of LYL314 (formerly IMPT-314) in large B-cell lymphoma will be presented...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?